ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

2 days ago · Third Quarter 2024 Financial Results. Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, …

CouponFollow Extension

52%
OFF

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

2 days ago · Third Quarter 2024 Financial Results. Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, …

biospace.com

$2
OFF

ENDRA Life Sciences Reports Q3 2024 Results And Progress

1 week from now

18 hours ago · Financially, ENDRA reported a net loss of $2.4 million for the quarter, an improvement from the previous year’s $3.1 million loss, largely due to reduced operating costs.

businessinsider.com

52%
OFF

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

2 days ago · Third Quarter 2024 Financial Results Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, and …

morningstar.com

$4
OFF

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

3 days ago · Financial Results for the Third Quarter 2024: R&D Expenses : Research and development expenses for the quarter ended September 30, 2024 , were $4.4 million , …

nasdaq.com

52%
OFF

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

Sep 30, 2024 · Operating expenses in the third quarter of 2024 were down 52% to $1.5 million compared with $3.1 million in the third quarter in 2023, and down 32% compared with the …

stockhouse.com

$7
OFF

Kezar Life Sciences Reports Third Quarter 2024 Financial Results …

1 week from now

4 days ago · Research and development (R&D) expenses for the third quarter of 2024 decreased by $7.5 million to $16.2 million, compared to $23.7 million in the third quarter of 2023. This …

biospace.com

FAQs about ENDRA Life Sciences Reports Third Quarter 2024 Financial Results … Coupon?

How did Endra life sciences perform in Q3 2024?

In its recent earnings report for the third quarter of 2024, ENDRA Life Sciences highlighted significant advancements in its TAEUS platform, a reduction in operating expenses, and progress in clinical studies aimed at regulatory submission. ...

What information has Endra Life Sciences presented to its investors?

Here is a breakdown of the information Endra Life Sciences presented to its investors. ENDRA Life Sciences Inc., a company at the forefront of medical technology, specializes in Thermo Acoustic Enhanced UltraSound (TAEUS®) to measure liver fat content, targeting the healthcare industry, particularly for chronic liver conditions. ...

How much Endra life sciences stock have insiders bought?

In the past three months, ENDRA Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,043.00 in company stock and sold $0.00 in company stock. Only 0.71% of the stock of ENDRA Life Sciences is held by insiders. Only 1.19% of the stock of ENDRA Life Sciences is held by institutions. ...

Where can I get a replay of the Endra call?

A webcast of the call can also be accessed at ENDRA’s Investor Relations page and here A telephone replay will be available until April 4, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 8041087. ...

Who is Endra's new CEO Alexander Tokman?

Subsequent to quarter-end, ENDRA announced leadership changes. Board member Alexander Tokman was appointed as acting CEO, bringing 24+ years of global commercial leadership experience. Additionally, two industry veterans joined in key roles including regulatory and clinical affairs, and finance. ...